Biomerica Plunges 12.25% Amid Reverse Split, UAE Approval

On August 15, 2025, Biomerica's stock experienced a significant drop of 12.25% in pre-market trading, marking a notable decline in its share price.

Biomerica recently performed a 1 for 8 reverse stock split, which means shareholders now hold one share for every eight shares they previously held. This corporate action can impact the stock's liquidity and trading dynamics, potentially contributing to the recent price volatility.

Biomerica's Fortel® Ulcer Test has received approval for home use in the United Arab Emirates, enabling quicker detection of H. pylori infections. This regulatory approval is a significant milestone for the company, as it expands the market for its diagnostic product and could potentially drive future revenue growth.

Despite the recent approval, the stock's performance has been influenced by various factors, including liquidity shifts, short-covering, and speculative buying. The absence of fundamental news or technical indicators suggests that the price movements are driven by short-term market dynamics rather than underlying company performance.